Research location
Haine-Saint-Paul
Belgium
Advertisement
Research activity in Haine-Saint-Paul
BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 61 trials and 61 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Haine-Saint-Paul
61 linked trials · page 1 of 2Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsNCT07106632 · 2026-06-26 · 1 site observation
RECRUITING
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121 · 2025-07-15 · 1 site observation
RECRUITING
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15 · 1 site observation
RECRUITING
DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732 · 2023-10-24 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT05894239 · 2023-09-08 · 1 site observation
RECRUITING
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)NCT04916613 · 2022-04-19 · 1 site observation
RECRUITING
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLCNCT06219317 · 2025-01-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · 2023-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Left Bundle Branch Area Pacing Using Conventional Stylet-driven Pacemaker Leads for Cardiac Resynchronization TherapyNCT05365568 · 2022-09-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Registry of Laparoscopic Bariatric Surgery Using Stapling Devices: Observation of Safety and Clinical EfficacyNCT04808206 · 2022-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNCT05211895 · 2022-02-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)NCT04862663 · 2021-05-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerNCT04691804 · 2021-03-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)NCT04656652 · 2020-12-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Dissecting the Pathways of Therapy Resistance in Early Breast CancerNCT04995575 · 2020-07-08 · 1 site observation
TERMINATED
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerNCT04214288 · 2020-04-22 · 1 site observation
ACTIVE_NOT_RECRUITING
BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in BelgiumNCT03959137 · 2019-06-03 · 1 site observation
COMPLETED
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPNCT03899077 · 2019-04-05 · 1 site observation
UNKNOWN
Treatment Resistance Following Anti-cancer TherapiesNCT04436120 · 2019-02-13 · 1 site observation
TERMINATED
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)NCT03361865 · 2017-12-04 · 1 site observation
COMPLETED
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate CancerNCT02799706 · 2017-09-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)NCT03061812 · 2017-04-11 · 1 site observation
COMPLETED
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)NCT03033511 · 2017-02-07 · 1 site observation
TERMINATED
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesNCT02854436 · 2016-08-31 · 1 site observation
COMPLETED
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)NCT02585778 · 2015-10-23 · 1 site observation
COMPLETED
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra TreatmentNCT02031471 · 2014-01-01 · 1 site observation
COMPLETED
A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)NCT01926886 · 2013-11-19 · 1 site observation
COMPLETED
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerNCT01957436 · 2013-11-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1NCT01597414 · 2013-06-01 · 1 site observation
COMPLETED
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast CancerNCT01548677 · 2013-04-01 · 1 site observation
COMPLETED
A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid ArthritisNCT01834807 · 2013-04-01 · 1 site observation
COMPLETED
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in MonotherapyNCT01705730 · 2012-07-31 · 1 site observation
COMPLETED
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine TreatmentNCT01564056 · 2012-04-12 · 1 site observation
COMPLETED
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate CancerNCT01308580 · 2011-04-01 · 1 site observation
COMPLETED
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast CancerNCT01186991 · 2011-03-01 · 1 site observation
COMPLETED
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)NCT01219933 · 2011-01-01 · 1 site observation
COMPLETED
Male Breast Cancer: Understanding the Biology for Improved Patient CareNCT01101425 · 2010-12-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing RegimenNCT01254279 · 2010-12-01 · 1 site observation
COMPLETED
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)NCT01026142 · 2010-01-26 · 1 site observation
COMPLETED
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast CancerNCT01091168 · 2009-07-01 · 1 site observation
COMPLETED
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) PatientsNCT00722267 · 2008-07-01 · 1 site observation
COMPLETED
CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)NCT00681122 · 2008-05-01 · 1 site observation
COMPLETED
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast CancerNCT00553410 · 2007-08-01 · 1 site observation
COMPLETED
Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastNCT00470236 · 2007-06-01 · 1 site observation
UNKNOWN
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation
COMPLETED
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)NCT00409188 · 2007-01-01 · 1 site observation
COMPLETED
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast CancerNCT00338247 · 2006-07-01 · 1 site observation
APPROVED_FOR_MARKETING
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT00806923 · 2005-02-01 · 1 site observation
COMPLETED
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT00949910 · 2004-11-01 · 1 site observation
COMPLETED
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane TherapyNCT00067314 · 2003-06-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.